Steve
VOD Patient

Corporate Overview

August 5, 2020

Jazz Pharmaceuticals

Forward-Looking Statements

“SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

This slide deck and the accompanying oral presentation contain forward-looking statements, including, but not limited to, statements related to Jazz Pharmaceuticals’ future financial and operating results, including updated 2020 financial guidance and 2020 milestones and goals; the company’s growth strategy and expectations for growth; planned, ongoing and future clinical trials and other product development activities and regulatory events; ongoing and future product launches; the company’s corporate development efforts; the timing of the foregoing events and activities; the company’s expectation that oxybate net sales and AG royalties will meaningfully contribute to future total revenues; and other statements that are not historical facts. These forward-looking statements are based on the company’s current plans, objectives, estimates, expectations and intentions and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with: the ultimate duration and severity of the COVID19 pandemic and resulting global economic, financial and healthcare system disruptions and the current and potential future negative impacts to the company’s business operations and financial results; maintaining or increasing sales of and revenue from Xyrem; effectively launching and commercializing the company’s other products and product candidates; the time-consuming and uncertain regulatory approval process, including the risk that the company’s planned regulatory submissions may not be submitted, accepted or approved by applicable regulatory authorities in a timely manner or at all; the costly and time-consuming pharmaceutical product development and the uncertainty of clinical success, including risks related to failure or delays in successfully initiating or completing clinical trials; protecting and enhancing the company’s intellectual property rights; delays or problems in the supply or manufacture of the company’s products and product candidates; complying with applicable U.S. and non-U.S. regulatory requirements; government investigations, legal proceedings and other actions; obtaining and maintaining adequate coverage and reimbursement for the company’s products; identifying and acquiring, in-licensing or developing additional products or product candidates, financing these transactions and successfully integrating acquired product candidates, products and businesses; the company’s ability to realize the anticipated benefits of its collaborations with third parties for the development of product candidates; the ability to achieve expected future financial performance and results and the uncertainty of future tax and other provisions and estimates; and other risks and uncertainties affecting the company, including those described from time to time under the caption “Risk Factors” and elsewhere in Jazz Pharmaceuticals plc’s Securities and Exchange Commission filings and reports (Commission File No. 001-33500), including the company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2020 and future filings and reports by the company. In addition, while the company expects the COVID-19 pandemic to continue to adversely affect its business operations and financial results, the extent of the impact on the company’s ability to generate sales of and revenues from its approved products, execute on new product launches, its clinical development and regulatory efforts, its corporate development objectives and the value of and market for its ordinary shares, will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration and severity of the pandemic, governmental “stay-at-home” orders and travel restrictions, quarantines, social distancing and business closure requirements in the U.S., Ireland and other countries, and the effectiveness of actions taken globally to contain and treat the disease. Moreover, other risks and uncertainties of which the company is not currently aware may also affect the company’s forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements made in this slide deck and the accompanying oral presentation are made only as of the date hereof or as of the dates indicated in the forward-looking statements, even if they are subsequently made available by the company on its website or otherwise. The company undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made.

Focused Strategies to Meet Long-Term Objectives

DIVERSE PORTFOLIO

Neuroscience, including sleep medicine and movement disorders

Oncology, including hematologic malignancies and solid tumors



ROBUST AND EXPANDING R&D PORTFOLIO

Early- to late-stage studies in core areas focused on differentiated products for unmet needs

DISCIPLINED CAPITAL ALLOCATION

Balanced to support portfolio growth opportunities, corporate development and shareholder returns

EXECUTING GROWTH STRATEGY

Portfolio growth in key therapeutic areas (internal / external innovation), operational efficiency and globalization

Robust Evolution of Jazz Over Past 5 Years

BUSINESS EXPANSION, INCLUDING NEAR DOUBLING OF REVENUES

[1] Non-GAAP adjusted R&D spend, unaudited.

Our Execution Has Led to 9 Major Approvals in 5 Consecutive Years

5 MAJOR LAUNCHES IN 2020 – 2021*

2 POTENTIAL APPROVALS

2016
DEFITELIO (defibrotide sodium) injection 80 mg/mL
U.S. approval

2017
Vyxeos cytarabine and daunorubicin liposome for injection
U.S. approval

2018
Vyxeos cytarabine and daunorubicin liposome for injection
EMA approval

XYREM (sodium oxybate) oral solution
U.S. approval pediatric

2019
SUNOSI (solriamfetol)
U.S. approval

DEFITELIO (defibrotide sodium) injection 80 mg/mL
Japan approval[1]

2020
SUNOSI (solriamfetol)
EMA approval

ZEPZELCA (lurbinectedin)
U.S. approval

xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution
U.S. approval[2]

2021
Xywav
U.S. approval for idiopathic hypersomnia

JZP-458
U.S. approval for ALL

[1] Nippon Shinyaku Co., Ltd. has exclusive rights to develop and commercialize defibrotide in Japan. [2] FDA approved July 2020 for the treatment of cataplexy or EDS in narcolepsy.
* On track to execute up to 5 product launches through 2020 and 2021.



Financial Performance

Jazz Pharmaceuticals

Strong Financial Position to Execute on Key Objectives

GUIDANCE INCREASED DUE TO RESILIENCE OF THE BUSINESS

TOTAL REVENUES[1]
$ in millions



ADJUSTED NET INCOME PER DILUTED SHARE[3]



[1] 2016 to 2019 audited. [2] G=Guidance. Guidance provided by Jazz Pharmaceuticals plc on and as of August 4, 2020. Jazz Pharmaceuticals plc is not confirming or updating that guidance and actual results may differ.
[3] Reconciliations of GAAP net income to non-GAAP adjusted net income can be found in the Appendix at the end of this presentation. [4] Beginning in 2020, the company no longer excludes upfront and milestone payments from the company's non-GAAP adjusted net income, its line item components and non-GAAP adjusted EPS. The impact of this change to the company's 2020 non-GAAP adjusted net income and non-GAAP adjusted EPS guidance is approximately $175 million or $3.13 per diluted share, respectively, primarily related to the post-tax impact of the $200 million upfront payment made to PharmaMar in January 2020. For purposes of comparability, non-GAAP adjusted financial measures for 2016 to 2019 have been updated to reflect this change.

Broad Product Portfolio Contributing to Revenue Growth

NET PRODUCT SALES ($ IN MILLIONS)

NEUROSCIENCE

XYREM (sodium oxybate) oral solution

SUNOSI



ONCOLOGY

DEFITELIO (defibrotide sodium) injection 80 mg/mL

Vyxeos cytarabine and daunorubicin liposome for injection

ZEPZELCA (lurbinectedin) for injection 4 mg

Erwinaze asparaginase Erwinia chrysanthemi



Charts not to scale.

[1] 2019 audited. [2] G=Guidance. Guidance provided by Jazz Pharmaceuticals plc on and as of August 4, 2020. Jazz Pharmaceuticals plc is not confirming or updating that guidance and actual results may differ.

[3] Guidance includes minimal net sales of Xywav with an expectation to launch in 4Q20. [4] Guidance includes Zepzelca net sales following launch in 3Q20.

Strong Commitment to R&D

PRIORITIZING INVESTMENTS IN OUR MOST IMPORTANT CURRENT AND FUTURE REVENUE DRIVERS

TOTAL R&D SPEND[1]
$ in millions



R&D SPEND[1] AS % OF TOTAL REVENUES



[1] Non-GAAP adjusted R&D spend, unaudited. Reconciliations of GAAP R&D to non-GAAP adjusted R&D can be found in the Appendix at the end of this presentation. Beginning in 2020, the company no longer excludes upfront and milestone payments from the company's non-GAAP adjusted net income, its line item components and non-GAAP adjusted EPS. For purposes of comparability, non-GAAP adjusted financial measures for 2016 to 2019 have been updated to reflect this change. [2] G=Guidance. Guidance provided by Jazz Pharmaceuticals plc on and as of August 4, 2020. Jazz Pharmaceuticals plc is not confirming or updating that guidance and actual results may differ.

Neuroscience Update

Jazz Pharmaceuticals

Neuroscience Focus: Including Sleep Medicine and Movement Disorders

RECOGNIZED LEADER IN SLEEP DISORDERS

SLEEP DISORDERS

EDS in Narcolepsy
Cataplexy in Narcolepsy
EDS in OSA
Idiopathic Hypersomnia

MOVEMENT DISORDERS

Essential Tremor

Our Narcolepsy Focus

COMMITTED TO DEVELOPING LIFE-CHANGING THERAPIES FOR PATIENTS

CHRONIC, NEUROLOGIC SLEEP DISORDER

Narcolepsy affects 1 in 2,000

UNDERTREATED AND UNDERDIAGNOSED

In U.S. fewer than 50%, or 75,000 patients, are diagnosed/drug-treated

REQUIRES LIFE-LONG TREATMENT

Narcolepsy patients are at increased risk for stroke, heart attack/failure and death

A New Differentiated Standard of Oxybate Therapy

xywav™

XYWAV: FDA APPROVED JULY 2020 FOR TREATMENT OF CATAPLEXY OR EDS IN NARCOLEPSY

Unmet Need	• Narcolepsy is a chronic sleep disorder requiring life-long treatment • Narcolepsy patients are at increased risk of CV mortality and morbidity

Opportunity	• Xywav has a unique composition of cations resulting in 92% less sodium than current standard of care
	  • 1,000 to 1,500 mg less sodium per night in a medication that is taken chronically
	• Multiple and flexible Xywav dosing options available for adult and pediatric patients
	  • Existing Xyrem patients can readily cross over to Xywav at the same dose level
	• Xywav label, unlike Xyrem, does not include a warning to prescribers to monitor patients sensitive to sodium intake, including patients with heart failure, hypertension or renal impairment
	• Potential to become the oxybate treatment of choice for all patients, including:
	  • Current Xyrem patients, patients who previously were not prescribed Xyrem based on sodium concerns, as well as newly diagnosed narcolepsy patients
	• To ensure timely and broad patient access, Xywav will be priced at parity to Xyrem
	• Goal of having majority of oxybate patients on Xywav by 2023

Current Status	• Expected launch in 4Q20 following joint Xyrem/Xywav REMS implementation • Ongoing Phase 3 study in idiopathic hypersomnia, enrollment completed 1Q20 • Expect top-line data 4Q20; sNDA submission as early as 1Q21; targeting late 2021 launch

Expansion and Commercial Execution To Propel Future Revenue Growth

SUNOSI®

APPROVED IN THE U.S. AND EUROPE FOR THE TREATMENT OF EDS ASSOCIATED WITH OSA OR NARCOLEPSY

Unmet Need	• U.S.: ~50% of drug-treated OSA patients with EDS fail one or more traditional stimulants/WPAs • Europe: no approved pharmacotherapy agents for EDS in OSA
Opportunity	• U.S.: ~12 million diagnosed OSA patients, but only 6% currently drug-treated – Up to 50% of patients on CPAP therapy still report EDS[1] • Europe[2]: ~4 million diagnosed OSA patients; ~1 million with EDS
U.S. Current Status	• U.S. launch initiated July 2019 • Strong commercial coverage; >85% commercial lives covered for 2020 • 12% increase in U.S. prescriptions in 2Q20 compared to 1Q20, including strong patient refills
Europe Current Status	• European launch initiated in Germany in May 2020 • Building a commercial team in Europe • Rolling European launch to continue over next 18 months

[1] Antic NA, Catcheside P, Buchan C, et al. The Effect of CPAP in Normalizing Daytime Sleepiness, Quality of Life, and Neurocognitive Function in Patients with Moderate to Severe OSA. Sleep. 2011;34(1):111-119.
[2] France, Germany, Italy, Spain, UK

Expanding Our Neuroscience Focus Into Movement Disorders

JZP-385: POTENTIAL TO IMPROVE DEBILITATING SYMPTOMS OF ESSENTIAL TREMOR

Unmet Need	• Limited treatment options • Tolerability issues and lack of efficacy with currently available pharmacotherapy • ET ranges from mild to fully debilitating, with significant effects on quality of life and daily activities, such as eating, drinking, dressing and writing
Opportunity	• ET is the most common movement disorder • Incidence of ET increases and progressively worsens with age • In the U.S. and Europe[1]: – ~11 million prevalence, 2 million diagnosed, 500K drug-treated • First-in-class, best-in-class potential • May have applicability in other neurological conditions
Current Status	• Developed modified release formulation with once daily administration • Expect to initiate new healthy volunteer study August 2020 • Start-up activities for Phase 2b study to begin this year • Expect to initiate Phase 2b study early 2021

[1] France, Germany, Italy, Spain, UK



Oncology Update

Jazz Pharmaceuticals

Strategic Evolution in Oncology to Improve Outcomes in Cancer

FOCUSED EXPANSION INTO SOLID TUMORS WITH INNOVATIVE APPROACHES

HEMATOLOGICAL MALIGNANCIES

AML

ALL

Complications of HSCT

SOLID TUMORS

Zepzelca[1]

Pan-RAF inhibitor

Exosome targets[2,3]

CombiPlex

[1] Exclusive U.S. license. [2] Partnered collaboration. [3] Solid tumors and hematological malignancies.

Zepzelca: Providing Relapsed SCLC Patients with an Improved Therapeutic Option

ZEPZELCA™ (lurbinectedin) for injection 4 mg

ACCELERATED U.S. APPROVAL IN JUNE 2020 AND LAUNCH IN JULY 2020

Indication	• For the treatment of adult patients with metastatic SCLC with disease progression on or after platinum-based chemotherapy
Unmet Need	• Limited treatment options for relapsed SCLC • Poor prognosis and low survival rates • High need for tolerable, effective 2L+ therapies
Opportunity	• Complements Jazz's oncology commercial assets and investigational efforts in solid tumors • ~30K cases of SCLC in 2019 in the U.S.

Current Status	• Jazz acquired U.S. rights to Zepzelca from PharmaMar in January 2020
	• Added to NCCN Clinical Practice Guidelines in Oncology for SCLC in July 2020
	  • Recommended treatment for relapsed SCLC patients
	  • Preferred treatment for patients who relapse up to 6 months following prior systemic therapy
	• Actively working on development program in collaboration with PharmaMar
	• Phase 3 ATLANTIS study top-line data expected 2H20

Developing New Asparaginase Therapies for ALL

JZP-458 BLA SUBMISSION AS EARLY AS YEAR-END

Unmet Need	• L-asparaginase is an important component of ALL therapy • Patients who do not complete all of their prescribed asparaginase doses have significantly inferior EFS[1] • Alternative asparaginase therapies are needed to ensure that patients who develop hypersensitivity to *E. coli*-derived asparaginase are able to receive all prescribed asparaginase doses to complete their full treatment course
Opportunity	• ALL is most common form of cancer in children • ~15,000 ALL patients in U.S., Europe[2], Japan, Canada – In U.S., ~50% are pediatric patients and ~20% are adolescent and young adult • Hypersensitivity reactions are reported in up to 30% of patients[3]
Current Status	• Pivotal Phase 2/3 study in collaboration with COG enrolled first patient in December 2019 • Expect to enroll up to ~100 patients for IM administration with IV cohort to follow – IA at ~50 patients • Fast Track designation received October 2019 • Objective of launching in the U.S. in mid-2021

[1] DOI: 10.1200/JCO.2019.37.15_suppl.10005 *Journal of Clinical Oncology* 37, no. 15_suppl (May 20, 2019) 10005-10005. [2] France, Germany, Italy, Spain, UK. [3] Vrooman LM, et al. Pediatr Blood Cancer. 2010;54(2):199-205.

Strong R&D Execution

JZP-458: RAPID PROGRESSION FROM CONCEPT TO CLINIC IN COLLABORATION WITH FDA AND COG

AS PART OF OUR GLOBALIZATION EFFORTS, EXPECT TO MEET WITH EX-U.S. REGULATORY AUTHORITIES IN 2020

2020 Milestones/Goals

OPTIMIZING AND ADVANCING THE DEVELOPMENT PIPELINE

Neuroscience

- Xywav for IH
  - ✓ Completed Phase 3 enrollment 1Q20
  - – Top-line data 4Q20



Oncology

- JZP-458 for ALL pivotal Phase 2/3
  - – BLA submission as early as year-end
- Defitelio for prevention of acute GvHD
  - – Phase 2 top-line data late 2020

2020 Milestones/Goals

EXPANSION AND DIVERSIFICATION

3 Product Approvals

- ✓ Sunosi – EDS in OSA & Narcolepsy (Europe)
- ✓ Xywav – EDS & Cataplexy for Narcolepsy (U.S.)
- ✓ Zepzelca[1] – Relapsed SCLC (U.S.)

Regulatory Priorities

- ✓ Xywav – NDA submission 1Q20
- • JZP-458 – BLA submission as early as year-end

Corporate Development Activities

- • Expand portfolio through multiple acquisitions or partnerships

[1] Exclusive U.S. license, FDA accelerated approval June 2020.

JAZZ's Demonstrated Value Proposition

1. Diverse portfolio of commercialized products
2. Multiple growth drivers
   - Up to 5 product launches 2020 through 2021
3. Disciplined capital allocation
   - Focused investments in the business
   - Investing to diversify portfolio
4. Robust and expanding R&D portfolio
   - Enhanced R&D capabilities
   - Expanding our portfolio through internal and corporate development efforts
   - 4 corporate development transactions in 2019
5. Strong operational efficiency and globalization



Steve
VOD Patient

Appendix

Jazz Pharmaceuticals

Robust Early- to Late-Stage Pipeline Fueled by Strong R&D Investment

PRE-CLINICAL	PHASE 1	PHASE 2	PHASE 3
CombiPlex Hem/Onc exploratory activities	**JZP-324** Oxybate extended-release formulation	**JZP-385**[4] Essential tremor (Phase 2b)	**Xywav** Idiopathic hypersomnia
JZP-341 (Long-acting *Erwinia* asparaginase)[2] ALL/other hematological malignancies	**Vyxeos** Low Intensity Dosing for higher risk MDS[3]	**Defitelio** • Prevention of aGvHD • Prevention of CAR-T associated neurotoxicity	**JZP-458** (recombinant *Erwinia* asparaginase) ALL/LBL (pivotal Phase 2/3)
Recombinant pegaspargase[1] Hematological malignancies	**Vyxeos + other approved therapies** • R/R AML or HMA Failure MDS[3] • First-line, fit AML (Phase 1b) • Low Intensity Therapy for first-line, unfit AML (Phase 1b)	**Vyxeos** • HR-MDS (EMSCO)[5] • Newly diagnosed older adults with HR-AML[4,5]	**Zepzelca**[6] Relapsed SCLC (ATLANTIS)
Pan-RAF Inhibitor Program RAF & RAS mutant tumors	**IMGN632**[1] • R/R CD123+ Hematological malignancies • **+/- venetoclax/azacitidine in** CD123+ AML (Phase 1b/2)	**Vyxeos + venetoclax** *de novo* or R/R AML[3]	**Vyxeos** • AML or HR-MDS >60 yrs (AML18) [5] • AML or HR-MDS >18 yrs (AML19) [5] • Newly diagnosed adults with standard- and HR-AML (AMLSG) [5] • Newly diagnosed <22 yrs with AML (COG)[5]
Exosome targets (NRAS, STAT3 and 3 others)[2] Hematological malignancies/solid tumors			
Defitelio Exploratory activities			

NEUROSCIENCE
ONCOLOGY

[1] Opt-in opportunity. [2] Partnered collaboration. [3] Jazz & MD Anderson Cancer Center collaboration study. [4] Planned. [5] Cooperative group study. [6] Exclusive U.S. license.

Oxybate Landscape

OXYBATE NET SALES AND AG ROYALTIES EXPECTED TO CONTRIBUTE MEANINGFULLY TO TOTAL REVENUES



[1] Hikma AG entry on January 1, 2023 with initial 6-month AG term and optional AG terms from July 1, 2023 to December 31, 2027; Amneal, Lupin and Par AG entry with low single-digit volume restrictions on July 1, 2023; Launch dates provided in settlement agreements with ANDA filers could be accelerated under certain circumstances. [2] Hikma has a license to launch its generic product as of July 1, 2023, but it will no longer have the right to sell an AG product through the Xyrem REMS if it elects to do so. [3] Subject to obtaining or maintaining ANDA approval.

Non-GAAP Financial Measures

To supplement Jazz Pharmaceuticals' financial results and guidance presented in accordance with U.S. generally accepted accounting principles (GAAP), the company uses certain non-GAAP (also referred to as adjusted or non-GAAP adjusted) financial measures in this presentation and the accompanying tables. In particular, the company presents non-GAAP adjusted net income (and the related per share measure) and its line item components, as well as certain non-GAAP adjusted financial measures derived therefrom, including non-GAAP adjusted gross margin percentage and non-GAAP adjusted effective tax rate. Non-GAAP adjusted net income (and the related per share measure) and its line item components exclude from GAAP reported net income (and the related per share measure) and its line item components certain items, as detailed in the reconciliation tables that follow, and in the case of non-GAAP adjusted net income (and the related per share measure), adjust for the income tax effect of non-GAAP adjustments and, as applicable, the income tax benefit related to an intra-entity intellectual property asset transfer and the impact of the U.S. Tax Cuts and Job Act (U.S. Tax Act). In this regard, the components of non-GAAP adjusted net income, including non-GAAP cost of product sales, non-GAAP SG&A expenses and non-GAAP R&D expenses, are income statement line items prepared on the same basis as, and therefore components of, the overall non-GAAP adjusted net income measure.

The company believes that each of these non-GAAP financial measures provides useful supplementary information to, and facilitates additional analysis by, investors and analysts. In particular, the company believes that each of these non-GAAP financial measures, when considered together with the company's financial information prepared in accordance with GAAP, can enhance investors' and analysts' ability to meaningfully compare the company's results from period to period and to its forward-looking guidance, and to identify operating trends in the company's business. In addition, these non-GAAP financial measures are regularly used by investors and analysts to model and track the company's financial performance. Jazz Pharmaceuticals' management also regularly uses these non-GAAP financial measures internally to understand, manage and evaluate the company's business and to make operating decisions, and compensation of executives is based in part on certain of these non-GAAP financial measures. Because these non-GAAP financial measures are important internal measurements for Jazz Pharmaceuticals' management, the company also believes that these non-GAAP financial measures are useful to investors and analysts since these measures allow for greater transparency with respect to key financial metrics the company uses in assessing its own operating performance and making operating decisions.

These non-GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable GAAP measures; should be read in conjunction with the company's consolidated financial statements prepared in accordance with GAAP; have no standardized meaning prescribed by GAAP; and are not prepared under any comprehensive set of accounting rules or principles. In addition, from time to time in the future there may be other items that the company may exclude for purposes of its non-GAAP financial measures; and the company has ceased, and may in the future cease, to exclude items that it has historically excluded for purposes of its non-GAAP financial measures. For example, commencing in 2020, the company no longer excludes upfront and milestone payments from the company's non-GAAP adjusted net income, its line item components and non-GAAP adjusted EPS. For purposes of comparability, non-GAAP adjusted financial measures for the years 2016 to 2019 have been updated to reflect this change. Accordingly, such payments are not excluded from its non-GAAP financial measures for years 2016 to 2019, or from 2020 non-GAAP adjusted net income guidance and non-GAAP adjusted net income per diluted share guidance as detailed in the reconciliation tables that follow. Likewise, the company may determine to modify the nature of its adjustments to arrive at its non-GAAP financial measures. Because of the non-standardized definitions of non-GAAP financial measures, the non-GAAP financial measures as used by Jazz Pharmaceuticals in this press release and the accompanying tables have limits in their usefulness to investors and may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by other companies.

Reconciliation of GAAP Reported to Non-GAAP Adjusted Net Income

In millions, except per share amounts (unaudited)	2016	2017	2018	2019	2020 Guidance[3]
GAAP net income[1]	$ 396.8	$ 487.8	$ 447.1	$ 523.4	$190 - $270[3]
Intangible asset amortization	102.0	152.1	201.5	354.8	250 – 270[3]
Share-based compensation expense	98.8	106.9	102.4	110.6	120 – 135
Loss contingency	--	--	57.0	--	--
Impairment charges and disposal costs	--	--	44.0	--	136
Acquired IPR&D asset acquisition	--	--	--	48.3	--
Transaction and integration related costs	13.6	--	--	--	--
Expenses related to certain legal proceedings and restructuring	6.1	6.0	--	--	--
Non-cash interest expense	22.1	30.0	44.0	46.4	50 – 60
Loss on extinguishment and modification of debt	0.6	--	--	--	4
Income tax effect of above adjustments	(34.8)	(46.1)	(59.5)	(85.9)	(105) - (115)
Income tax benefit related to intra-entity intellectual property asset transfer	--	--	--	(112.3)	--
U.S. Tax Act impact	--	(148.8)	(7.5)	--	--
Non-GAAP adjusted net income[2]	$ 605.3	$ 587.9	$ 829.0	$ 885.2	$670 - $730
GAAP net income per diluted share[1]	$ 6.41	$ 7.96	$ 7.30	$ 9.09	$3.40 - $4.85
Non-GAAP adjusted net income per diluted share[2]	$ 9.78	$ 9.59	$ 13.54	$ 15.38	$11.90 - $13.00
Weighted-average ordinary shares used in diluted per share calculation	61.9	61.3	61.2	57.6	56

Note: Amounts may not total due to rounding.
[1] 2016 to 2019 audited. [2] Beginning in 2020, the company no longer excludes upfront and milestone payments from the company's non-GAAP adjusted net income, its line item components and non-GAAP adjusted EPS. For purposes of comparability, non-GAAP adjusted financial measures for 2016 to 2019 have been updated to reflect this change. [3] Guidance provided by Jazz Pharmaceuticals plc on and as of August 4, 2020. Jazz Pharmaceuticals plc is not confirming or updating that guidance and actual results may differ.

Reconciliation of GAAP R&D to Non-GAAP Adjusted R&D Expense

In millions (unaudited)	**2016**	**2017**	**2018**	**2019**	**2020G[3]**
GAAP R&D expense[1]	$162.3	$198.4	$226.6	$299.7	$302 - $338
Share-based compensation expense	(15.3)	(17.9)	(19.0)	(25.2)	(27-33)
Transaction and integration related costs	(0.5)	--	--	--	--
Non-GAAP adjusted R&D expense[2]	$146.5	$180.6	$207.6	$274.5	$275 - $305

Note: Amounts may not total due to rounding.
[1] 2016 to 2019 audited. [2] Beginning in 2020, the company no longer excludes upfront and milestone payments from the company's non-GAAP adjusted net income, its line item components and non-GAAP adjusted EPS. For purposes of comparability, non-GAAP adjusted financial measures for 2016 to 2019 have been updated to reflect this change. [3] G=Guidance; Guidance provided by Jazz Pharmaceuticals plc on and as of August 4, 2020. Jazz Pharmaceuticals plc is not confirming or updating that guidance and actual results may differ.

Glossary of Terms

2L = Second-Line
AG = Authorized Generic
aGvHD = Acute Graft vs Host Disease
ALL = Acute Lymphoblastic Leukemia
AML = Acute Myeloid Leukemia
AMLSG = AML Study Group
Amneal = Amneal Pharmaceuticals LLC
ANDA = Abbreviated New Drug Application
ATLANTIS = Phase 3 Clinical Study of lurbinectedin in SCLC
BLA = Biologics License Application
CAR-T = Chimeric Antigen Receptor T-cell Therapy
COG = Children's Oncology Group
COVID-19 = Coronavirus Disease of 2019
CNS = Central Nervous System
CPAP = Continuous Positive Airway Pressure
CV = Cardiovascular
EDS = Excessive Daytime Sleepiness
EFS = Event Free Survival
EMSCO = European Myelodysplastic Syndromes Cooperative Group
EPS = Earnings Per Share
ET = Essential Tremor
FDA = U.S. Food and Drug Administration
GAAP = Generally Accepted Accounting Principles
GvHD = Graft vs Host Disease
Hem/Onc = Hematology/Oncology
Hikma = Hikma Pharmaceuticals PLC
HMA = Hypomethylating Agent
HR-AML = High-Risk AML
HR-MDS = High-Risk MDS
HSCT = Hematopoietic Stem Cell Transplant
IA = Interim Analysis
IH = Idiopathic Hypersomnia
IM = Intramuscular
IMGN = ImmunoGen, Inc.
IND = Investigational New Drug Application
IPR&D = In-Process Research & Development
IV = Intravenous
LBL = Lymphoblastic Lymphoma
Lupin = Lupin, Inc.
MDS = Myelodysplastic Syndrome
NCCN = National Comprehensive Cancer Network
NDA = New Drug Application
OSA = Obstructive Sleep Apnea
Par = Par Pharmaceuticals, Inc.
Pfenex = Pfenex, Inc.
PharmaMar = Pharma Mar, S.A.
PRV = Priority Review Voucher
R&D = Research & Development
REMS = Risk Evaluation Mitigation Strategy
R/R = Relapsed/Refractory
SCLC = Small Cell Lung Cancer
SG&A = Selling, General & Administrative Expense
VOD = Hepatic Veno-occlusive Disease
WPA = Wake Promoting Agent

Xyrem® (sodium oxybate) Boxed Warning

WARNING: CENTRAL NERVOUS SYSTEM DEPRESSION and ABUSE AND MISUSE.

Central Nervous System Depression

Xyrem (sodium oxybate) is a CNS depressant. In clinical trials at recommended doses, obtundation and clinically significant respiratory depression occurred in adult patients treated with Xyrem. Many patients who received Xyrem during clinical trials in narcolepsy were receiving central nervous system stimulants.

Abuse and Misuse

Xyrem® (sodium oxybate) is the sodium salt of gamma-hydroxybutyrate (GHB). Abuse or misuse of illicit GHB, either alone or in combination with other CNS depressants, is associated with CNS adverse reactions, including seizure, respiratory depression, decreases in the level of consciousness, coma, and death.

Because of the risks of CNS depression and abuse and misuse, Xyrem is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the Xyrem REMS Program. Further information is available at www.XYREMREMS.com or 1-866-XYREM88® (1-866-997- 3688).

Xyrem (sodium oxybate) prescribing information

Xywav™ (calcium, magnesium, potassium, and sodium oxybates) oral solution

Boxed Warning

WARNING: CENTRAL NERVOUS SYSTEM DEPRESSION and ABUSE AND MISUSE.

Central Nervous System Depression

XYWAV is a CNS depressant. Clinically significant respiratory depression and obtundation may occur in patients treated with XYWAV at recommended doses *[see Warnings and Precautions (5.1, 5.4)]*. Many patients who received XYWAV during clinical trials in narcolepsy were receiving central nervous system stimulants *[see Clinical Trials (14.1)]*.

Abuse and Misuse

The active moiety of XYWAV is oxybate or gamma-hydroxybutyrate (GHB). Abuse or misuse of illicit GHB, either alone or in combination with other CNS depressants, is associated with CNS adverse reactions, including seizure, respiratory depression, decreases in the level of consciousness, coma, and death *[see Warnings and Precautions (5.2)].*

Because of the risks of CNS depression and abuse and misuse, XYWAV is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the XYWAV and XYREM REMS *[see Warnings and Precautions (5.3)]*.

Vyxeos® (daunorubicin and cytarabine) liposome for injection

Boxed Warning

WARNING: DO NOT INTERCHANGE WITH OTHER DAUNORUBICIN- AND/OR CYTARABINE-CONTAINING PRODUCTS

VYXEOS has different dosage recommendations than daunorubicin hydrochloride injection, cytarabine injection, daunorubicin citrate liposome injection, and cytarabine liposome injection. Verify drug name and dose prior to preparation and administration to avoid dosing errors *(5.1)*.

Vyxeos prescribing information